source
- FDA approves vepdegestrant for ESR1-mutated ER-positive advanced breast cancerOn May 1, 2026 the FDA gave its first approval to vepdegestrant, an oral selective estrogen receptor degrader, for adult patients with estrogen receptor-positive, HER2-negative breast cancer that c…
- Bristol Myers Squibb signs up to $15.2 billion partnership with China's Hengrui PharmaBristol Myers Squibb announced a licensing partnership with China's Hengrui Pharma covering more than a dozen early-stage drug programs. The agreement includes a $600 million upfront payment to He…